Markus Warmuth - 01 Jun 2026 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Reporting relationship: President & CEO, Director
Issuer ticker: GLUE
Reported as of: 01 Jun 2026
Net transaction value: -$106,253
SEC form: 4
Accepted by SEC: 02 Jun 2026, 16:05:24 UTC
Prior SEC filing: 05 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Markus Warmuth

Key filing fact

Markus Warmuth filed Form 4 for Monte Rosa Therapeutics, Inc. (GLUE) on 02 Jun 2026.

Key facts

This page summarizes Markus Warmuth's Form 4 filing for Monte Rosa Therapeutics, Inc. (GLUE).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 02 Jun 2026, 16:05.

Change

Previous filing in this sequence was filed on 05 May 2026.
Current net transaction value: -$106,253.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001855643 Primary reporting owner

Warmuth Markus

Relationship: President & CEO, Director
Address: MONTE ROSA THERAPEUTICS, INC., 321 HARRISON AVENUE, SUITE 900, BOSTON
Signature: /s/ Markus Warmuth
Signature date: 02 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GLUE transaction

Common Stock

Sale

Transaction value: $97,021
Shares: -4,998
Change %: -0.83%
Price: $19.41
Shares after: 595,006
Date: 01 Jun 2026
Ownership: Direct
Footnotes: F1, F2

GLUE transaction

Common Stock

Sale

Transaction value: $9,232
Shares: -468
Change %: -0.08%
Price: $19.73
Shares after: 594,538
Date: 01 Jun 2026
Ownership: Direct
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.69 to $19.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.69 to $19.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.